There currently are many brands of supplements on the market that contain palmitoylethanolamide (PEA). Our choice goes out to PEA capsules that have been clinically proven, are safe and of high quality (GRAS certified). Palmitoylethanolamide is a painkilling compound with anti-inflammatory properties that is naturally produced by the body. In 1993, Nobel Prize winner Rita Levi-Montalcini emphasized the significance of this natural substance. She helped create the first PEA tablet, which became available in Italy under the name Normast.

In 2007 an Italian company introduced Normast, which tablets contain 600mg of palmitoylethanolamide along with a number of other chemical pharmaceutical fillers. A few years later, Normast also became available as a powder (600mg) sweetened with sorbitol.

In 2015 the business Care-Pharmaceuticals introduced an innovated formula of palmitoylethanolamide in 400mg capsules. This PEA is completely free of chemical fillers, flavoring, coloring and sweeteners. In 2015 a new and optimized PEA preparation became available: PeaCure: specifically developed for the nervous system.

PeaCure capsules contain only finely ground palmitoylethanolamide, using a special method of production, and médication nothing else. This type of PEA is (PEA) proven to be effective and safe. This does not count for all other PEA products, which is concerning.

For this reason, always choose a PEA preparation with the PEA label. The safety and effectiveness (and often the purity) of other preparations have not been proven! The results obtained with PEA label certified PEA capsules are the only ones described by us in international medical literature.

A PEA cream has also been available for several years now. The producer of PeaCure recommends users to strengthen the benefits of PEA capsules with this cream, which works via the thin nerves of the skin.

PEA is produced in our body during chronic inflammation and chronic pain to restore balance. However, during chronic illness this production is often too low. In this case you can take an PEA supplement to restore balance.

PEA: the facts

There are many known facts about the substance Palmitoylethanolamide (PEA):

• PEA has been described in more than 500 scientific publications.
• The substance PEA and its structure were first described in 1953.
• Normast was the first PEA tablet to be introduced in this century to treat neurogenic inflammation & neuralgic pain.
• PEA has been used by millions of people worldwide.
• PEA can effectively be used for a multitude of chronic pain complaints, including pains due to hernia, diabetes, chemotherapy, nerve pain and arthritis.
• PEA can also be used for chronic inflammation, like inflammation of the prostate, the bladder (if not bacterial) and chronic inflammation of the intestines (colitis ulcerosa).
• PEA can safely be used in combination with other supplements and medication.
• PEA is an all-natural bodily substance.
• PEA is present in all animals to restore balance, except in insects.
• PEA is produced in our bodies and restores balance.
• PEA is also present in foods like meat, eggs, soybeans and peanuts.
• PEA has no side effects and is easily broken down by the body’s own enzymes.
• PEA doesn’t put strain on the kidneys and liver.
• PEA was first mentioned as a natural treatment for advanced disease symptoms by Italian Nobel Prize winner Professor Rita Levi-Montalcini in 1993.
• PEA first became available as a GMP certified capsule in the United States in 2011. Meanwhile there are many copycat remedies on the market of unclear quality and origin, which we don’t recommend, and that have not been clinically tested.

PeaCure is a prescription free food supplement. The benefit of PEA is that it can almost always be used as a natural method to treat chronic pain and inflammation without negative side effects. PEA can also be safely combined with regular medicine, as no negative interactions have been recorded.

Dosage and usage of PeaCure

The most researched and most effective dosage is 1200 mg of PEA per day. Which means either 600mg of Normast tablets twice daily or 400mg PeaCure capsules three times a day. The PeaCure capsules don’t have to be taken in 3 dosages spread over the day; twice a day is ok as well. For example 2 capsules PeaCure in the morning after breakfast and one PeaCure in the evening after dinner.

Web page entirely about PEA

Below is a detailed piece about the biological meaning of palmitoylethanolamide, as found in PeaCure and Normast.

Palmitoylethanolamide slows the activity of so-called mast cells, certain inflammatory cells, and also contains painkilling and anti-inflammatory properties due to the specific activity on a certain important receptor in the cell nucleus, the PARR-receptor. But PEA, as a biological molecule, has an entire series of natural points of application, which are represented in the model below.

This is why it’s easy to understand why palmitoylethanolamide can be used for so many symptoms. What all these illnesses have in common in chronic pain or inflammation.

Here you find the potential circle of indications for palmitoylethanolamide, based on pharmaceutical studies, pre-clinical studies and clinical studies, as well as our personal experiences at the Institute for neuropathic pain.

This circle of indications was originally designed by the Institute for Neuropathic pain for intercollegiate consult with doctors who turn to the institute concerning treatments of their patients. The circle is not meant as a claim for the effectiveness of Normast or PeaCure in all of these indications.

Circle of Indications for Palmitoylethanolamide

Because palmitoylethanolamide slows the activity of mast cells, on top of that of nerve cells and glia cells that get overworked during chronic pain, the below indications for this substance are understandable based on the pathogenesis. Slowing down the derailing of mast cells and other inflammatory cells happens through the so-called nucleus receptors in the cells.

Chronic pain syndromes

General Chronic pain syndromes [5] [6] [7][9] [10][9][12][13][14][15][16] [17][18][19]
Pain and spasms due to MS [20]
Hernia and back pain [21] [22] [23] [24][25]
Diabetic neuropathic pains [26] [27] [28] [27] [30]
Herpes Zoster pain (shingles) [31][32]
Neuropathic pain due to different forms of neuropathy, CIAP, CIDP, etc. [13] [34]
Carpal tunnel syndrome [35] [36]
Pain due to chemotherapy [37]
Complex regional pain syndrome, Sudeck [38] [1]
Pain and painful spasms due to MS [39] [40] [41] [42] [43][44] [45][46][47][48][49]
Central neuropathic pain due to stroke [50][51][52][53][54]
Central neuropathic pain due to Syringomyelia and Paraplegia [39] [56]
Migraine [57] [58] [60]
Fibromyalgia [61] [2]
Rheumatoid Arthritis and Bechterew pains [62] [63][64]
Psoriatic Arthritis [65]
Costen Syndrome and Temporomandibulair pain disorder [66]
Chronic Pruritus, unexplained itch [67]
Pain and itching after chemotherapy [68]
Occipital Neuralgia [3]

Pain in bladder, prostate and vagina

In case of unexplained painful inflammation, when the urologist has ruled out cancer en there is no case of chronic infection due to bacteria, the anti-inflammatory and painkiller PeaCure or Normast is a good move. This remedy regulates the excessively active inflammatory cells and reduces pain.

Chronic prostate pain complaints

Chronic prostate pain (prostatodynia) [69][69][71]

When the Gynecologist or urologist ruled out infection and there is unexplained inflammation in the inside of the bladder, with pain, difficulty urinating, urinating small quantities etc, taking Normast or PeaCure can be useful.

Chronic pain the bladder
Interstitial cystitis [73]
Chronic bladder pain [74][75][76]

Ailments of the reproductive organs
Lichen planus with itching and pain [78]
Vulvar vestibulitis [79][80] [81] [82]
Vulvodynia, vestibulodynia [83] [84]
Perineodynia (unexplained pain in the pelvis) [85]
Endometriosis [86]
Menstruation pains [87]

Intestinal problems
Intestinal (and colon) inflammation and pain syndromes [10] [89] [90]
Ulcerative Colitis [91] [92] [93]
Crohn’s disease [94] [95]
Irritable bowel syndrome [96] [97]
Proctitis [98][99] [98]
Chronic unexplained stomach aches [101] [97]

Skin conditions
Chronic unexplained skin inflammation [17] [104] [106] [107]
Chronic unexplained itching [108][67]
Atopic and contact dermatitis [110] [111] [112][113][114][115][116]
Psoriasis [117] [118] [119]
Notalgia paresthetica

Other conditions
Asthma and COPD [120] [121][122]
Hay fever and allergic rhinitis [123]
Angina pectoris and Kounis syndrome [124] [125][126]
Progressive arteriosclerosis [127]
Ocylar hypertension [129] [130]
Depression [131]
Alzheimer and Parkinson’s disease [133] [7]
Paraplegia [39]

More literature about PEA under this link.

References

[1]: Weller CL, Collington SJ, Williams T, Lamb JR. | Mast cells in health and disease. | Clin Sci (Lond). | 2011 Jun;120(11):473-84.
[2]: Yamashita M. | PPARalpha/gamma-Independent Effects of PPARalpha/gamma Ligands on Cysteinyl Leukotriene Production in Mast Cells. | PPAR Res. | 2008;2008:293538. Epub 2008 Nov 9.
[3]: Cabrero A, Laguna JC, Vázquez M. |Peroxisome proliferator-activated receptors and the control of inflammation. | Curr Drug Targets Inflamm Allergy. | 2002 Sep;1(3):243-8.
[4]: Tachibana M, Wada K, Katayama K, Kamisaki Y, Maeyama K, Kadowaki T, Blumberg RS, Nakajima A. | Activation of peroxisome proliferator-activated receptor gamma suppresses mast cell maturation involved in allergic diseases. | Allergy. | 2008 Sep;63(9):1136-47. Epub 2008 Jun 10.
[5]: DiPaolo A et al. Palmitoylethanolamide as a treatment for vaious chronic painstates. Presented at the 34 AISD congress in Riccione, 2011 | |
[6]: D’Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, Mattace Raso G, Cuzzocrea S, Loverme J, Piomelli D, Meli R, Calignano A. | Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. | Eur J Pharmacol. | 2009 Jun 24;613(1-3):54-9. Epub 2009 Apr 20.
[7]: Scuderi C, Esposito G, Blasio A, Valenza M, Arietti P, Steardo L Jr, Carnuccio R, De Filippis D, Petrosino S, Iuvone T, Di Marzo V, Steardo L. | Palmitoylethanolamide counteracts reactive astrogliosis induced by beta-amyloid peptide. | J Cell Mol Med. | 2011 Jan 21. doi: 10.1111/j.1582-4934.2011.01267.x. [Epub ahead of print]
[8]: Cerrato S, Brazis P, della Valle MF, Miolo A, Puigdemont A. | Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells. | Vet Immunol Immunopathol. | 2010 Jan 15;133(1):9-15. Epub 2009 Jun 27.
[9]: Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. | The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. | Pain. | 2008 Oct 31;139(3):541-50. Epub 2008 Jul 3.
[10]: De Filippis D, D’Amico A, Iuvone T. | Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. | J Neuroendocrinol. | 2008 May;20 Suppl 1:20-5.
[11]: Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. | The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a Access murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. | Pain. | 2008 Oct 31;139(3):541-50. Epub 2008 Jul 3.
[12]: Jhaveri MD, Richardson D, Robinson I, Garle MJ, Patel A, Sun Y, Sagar DR, Bennett AJ, Alexander SP, Kendall DA, Barrett DA, Chapman V. | Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. |Neuropharmacology. | 2008 Jul;55(1):85-93. Epub 2008 Apr 29.
[13]: Wallace VC, Segerdahl AR, Lambert DM, Vandevoorde S, Blackbeard J, Pheby T, Hasnie F, Rice AS. | The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy. | Br J Pharmacol. | 2007 Aug;151(7):1117-28. Epub 2007 Jun 11.
[14]: LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G, Meli R, Hohmann A, Calignano A, Piomelli D. | Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. | J Pharmacol Exp Ther. |2006 Dec;319(3):1051-61. Epub 2006 Sep 22.
[15]: Farquhar-Smith WP, Rice AS. | Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. | Anesthesiology. | 2001 Mar;94(3):507-13; discussion 6A.
[16]: Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. | The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. | Pain. | 1998 May;76(1-2):189-99.
[17]: De Filippis D, Luongo L, Cipriano M, Palazzo E, Cinelli MP, de Novellis V, Maione S, Iuvone T. | Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. | Mol Pain. | 2011 Jan 10;7:3.
[18]: Matzke AJ, Weiger TM, Matzke MA. | Detection of a large cation-selective channel in nuclear envelopes of avian erythrocytes. | FEBS Lett. | 1990 Oct 1;271(1-2):161-4.
[19]: Ford GK, Kieran S, Dolan K, Harhen B, Finn DP. | A role for the ventral hippocampal endocannabinoid system in fear-conditioned analgesia and fear responding in the presence of nociceptive tone in rats. | Pain. | 2011 Aug 22. [Epub ahead of print]
[20]: Mancardi GL et al. Palmitoylethanolamide in neuropathic pain in MS patients. Presented at the 15yh Italian neurological meeting in Padua, 2009 | |
[21]: G. Guida, A. de Fabiani, F. Lanaia, A. Alexandre, G.M. Vassallo, L. Cantieri, M. de Martino, M. Rogai, S. Petrosino | La palmitoiletanolamida (Normast) en el dolor neuropatico cronico por lumbociatalgia de tipo compresivo: estudio clinico multicentrico. | Dolor | 2010, 25:35-42
[22]: Desio,P et al. | Efficacy of palmitoylethanolamide and oxycodon in patients with low back pain. Anesthesia and medicina critica (AMC) 2011, 2: 62-71. |
[23]: Palomba R et al. | Efficacy of palmitoylethanolamide as part of multimodal analgesic therapy in patients with low back pain. Presented at 33rd AISD congress, 2010, Florence |
[24]: Dominguez CM et al. Palmitoylethanolamide on standard care in lumbosciatic pain, a pragmatic trial. Preseted at 8th congres of Pain algologists, Madrid, 2010. | |
[25]: Canteri L et al. Reduction of analgesics in patients suffering from lumbosciatic pain, treated with palmitoylethanolamide. Dolor 2010 | 25:227-234 |
[26]: Biasiotta A, La Cesa S, Leone C, Di Stefano G, Truini A, Cruccu G. | Efficacy of palmitoylethanolamide in patients with painful neuropathy. A clincial and neurophysiological open study. Preliminary results. | , Volume 4, Issue 1, May 2010, Page 77. |
[27]: Matias I, Wang JW, Moriello AS, Nieves A, Woodward DF, Di Marzo V. | Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. |Prostaglandins Leukot Essent Fatty Acids. | 2006 Dec;75(6):413-8. Epub 2006 Oct 2.
[28]: Schifiliti C, et al. Efficacy of palmitoylethanolamide in pain and neuropathic symptoms in diabetic patients Presentation at IV congress of European Schock society, Taormina, 2011 | |
[29]: Matias I, Wang JW, Moriello AS, Nieves A, Woodward DF, Di Marzo V. | Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. |Prostaglandins Leukot Essent Fatty Acids. | 2006 Dec;75(6):413-8. Epub 2006 Oct 2.
[30]: Adiletta S et al. Pregabalin and Palmitoylethanolamide in diabetic neuropathic pain: an randomized clinical trial. Presented at the 34th AISD meeting, 2011, Riccione. | |
[31]: Phan NQ, Siepmann D, Gralow I, Ständer S. | Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. | J Dtsch Dermatol Ges. | 2010 Feb;8(2):88-91. Epub 2009 Sep 10.
[32]: Deslo. P. Combination of pregabalin and palmitoylethanolamide (PEA) for neuropathic pain treatment. | Pathos, 2010, 17,4:9-14 |
[33]: Wallace VC, Segerdahl AR, Lambert DM, Vandevoorde S, Blackbeard J, Pheby T, Hasnie F, Rice AS. | The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy. | Br J Pharmacol. | 2007 Aug;151(7):1117-28. Epub 2007 Jun 11.
[34]: Desio P, Pregabalin and Palmitoylethanolamide in the treatment of neuropathic pain. Pathos 2010l17:9-14 | |
[35]: Assini A, Laricchia D, Pizzo R, Pandolfini L, Belletti M, Colucci M, Ratto S. | P1577: The carpal tunnel syndrome in diabetes: clinical and electrophysiological improvement after treatment with palmitoylethanolamide | Eur J Neurol | 2010: 17(S3):295.
[36]: Conigliaro R, Drago V, Foster PS, Schievano C, Di Marzo V. | Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. | Minerva Med. | 2011 Apr;102(2):141-7.
[37]: Truina A et al. Palmitoylethanolamide improves pain and nerve function in patients suffering from chemotherapy induced neuropathy. CNS and neurological drug target, 2011, submitted. | |
[38]: Islam MS, Nilsson T, Rorsman P, Berggren PO. | Interaction with the inositol 1,4,5-trisphosphate receptor promotes Ca2+ sequestration in permeabilised insulin-secreting cells. | FEBS Lett. | 1991 Aug 19;288(1-2):27-9.
[39]: Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S. | Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. | Brain Behav Immun. | 2011 Feb 25. [Epub ahead of print]
[40]: Jean-Gilles L, Feng S, Tench CR, Chapman V, Kendall DA, Barrett DA, Constantinescu CS. | Plasma endocannabinoid levels in multiple sclerosis. | J Neurol Sci. | 2009 Dec 15;287(1-2):212-5. Epub 2009 Aug 20.
[41]: Zajicek JP, Apostu VI. | Role of cannabinoids in multiple sclerosis. | CNS Drugs. | 2011 Mar 1;25(3):187-201. doi: 10.2165/11539000-000000000-00000.
[42]: Loría F, Petrosino S, Mestre L, Spagnolo A, Correa F, Hernangómez M, Guaza C, Di Marzo V, Docagne F. | Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. | Eur J Neurosci. | 2008 Aug;28(4):633-41. Epub 2008 Jul 24.
[43]: Cabranes A, Venderova K, de Lago E, Fezza F, Sánchez A, Mestre L, Valenti M, García-Merino A, Ramos JA, Di Marzo V, Fernández-Ruiz J. | Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. | Neurobiol Dis. | 2005 Nov;20(2):207-17.
[44]: Maccarrone M, Bernardi G, Agrò AF, Centonze D. | Cannabinoid receptor signaling in neurodegenerative diseases: a potential role for membrane fluidity disturbance. | Br J Pharmacol. | 2011 Feb 16. doi: 10.1111/j.1476-5381.2011.01277.x. [Epub ahead of print]
[45]: Bisogno T, Di Marzo V. | Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. | CNS Neurol Disord Drug Targets. | 2010 Nov;9(5):564-73.
[46]: Correa F, Hernangómez-Herrero M, Mestre L, Loría F, Docagne F, Guaza C. | The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. | Brain Behav Immun. | 2011 May;25(4):736-49. Epub 2011 Feb 16.
[47]: Rossi S, Bernardi G, Centonze D. | The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. | Exp Neurol. | 2010 Jul;224(1):92-102. Epub 2010 Mar 29.
[48]: Loría F, Petrosino S, Hernangómez M, Mestre L, Spagnolo A, Correa F, Di Marzo V, Docagne F, Guaza C. | An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. | Neurobiol Dis. | 2010 Jan;37(1):166-76. Epub 2009 Oct 6.
[49]: Correa FG, Mestre L, Docagne F, Borrell J, Guaza C. | The endocannabinoid anandamide from immunomodulation to neuroprotection. Implications for multiple sclerosis. | Vitam Horm. | 2009;81:207-30.
[50]: Naccarato M, Pizzuti D, Petrosino S, Simonetto M, Ferigo L, Grandi FC, Pizzolato G, Di Marzo V. | Possible Anandamide and Palmitoylethanolamide involvement in human stroke. | Lipids Health Dis. | 2010 May 14;9:47.
[51]: Hansen HS. | Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain. | Exp Neurol. | 2010 Jul;224(1):48-55. Epub 2010 Mar 29.
[52]: Koch M, Kreutz S, Böttger C, Benz A, Maronde E, Ghadban C, Korf HW, Dehghani F. | Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-alpha. | Neurotox Res. | 2011 Feb;19(2):330-40. Epub 2010 Mar 11.
[53]: Schomacher M, Müller HD, Sommer C, Schwab S, Schäbitz WR. | Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. | Brain Res. | 2008 Nov 13;1240:213-20. Epub 2008 Sep 18.
[54]: Gray E, Ginty M, Kemp K, Scolding N, Wilkins A. | Peroxisome proliferator-activated receptor-α agonists protect cortical neurons from inflammatory mediators and improve peroxisomal function. | Eur J Neurosci. | 2011 Apr;33(8):1421-32. doi: 10.1111/j.1460-9568.2011.07637.x. Epub 2011 Mar 7.
[55]: Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S. | Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. | Brain Behav Immun. | 2011 Feb 25. [Epub ahead of print]
[56]: Genovese T, Esposito E, Mazzon E, Di Paola R, Meli R, Bramanti P, Piomelli D, Calignano A, Cuzzocrea S. | Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. | J Pharmacol Exp Ther. |2008 Jul;326(1):12-23. Epub 2008 Mar 26.
[57]: Sarchielli P, Pini LA, Coppola F, Rossi C, Baldi A, Mancini ML, Calabresi P. | Endocannabinoids in chronic migraine: CSF findings suggest a system failure. | Neuropsychopharmacology. | 2007 Jun;32(6):1384-90. Epub 2006 Nov 22.
[58]: Levy D. | Migraine pain, meningeal inflammation, and mast cells. | Curr Pain Headache Rep. | 2009 Jun;13(3):237-40.
[59]: Levy D, Burstein R, Strassman AM. | Mast cell involvement in the pathophysiology of migraine headache: A hypothesis.Headache. | 2006 Jun;46 Suppl 1:S13-8.
[60]: Zhang XC, Strassman AM, Burstein R, Levy D. | Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. | J Pharmacol Exp Ther. | 2007 Aug;322(2):806-12. Epub 2007 May 4.
[61]: Blanco I, Béritze N, Argüelles M, Cárcaba V, Fernández F, Janciauskiene S, Oikonomopoulou K, de Serres FJ, Fernández-Bustillo E, Hollenberg MD. | Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. | Clin Rheumatol.2010 Dec;29(12):1403-12. Epub 2010 Apr 30.
[62]: Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. | Mast cells: a cellular link between autoantibodies and inflammatory arthritis. | Science. | 2002 Sep 6;297(5587):1689-92.
[63]: Nigrovic PA, Lee DM. | Mast cells in autoantibody responses and arthritis. | Novartis Found Symp. | 2005;271:200-9; discussion 210-4.
[64]: Christy AL, Brown MA. | The multitasking mast cell: positive and negative roles in the progression of autoimmunity. | J Immunol. | 2007 Sep 1;179(5):2673-9.
[65]: Cañete JD, Celis R, Noordenbos T, Moll C, Gómez-Puerta JA, Pizcueta P, Palacin A, Tak PP, Sanmartí R, Baeten D. |Distinct synovial immunopathology in Behçet disease and psoriatic arthritis. | Arthritis Res Ther. | 2009;11(1):R17. Epub 2009 Feb 6.
[66]: Bortolotti F,Russo M, Bartolucci ML, Alessandri Bonetti G, Gatto MR, Marini I. | Palmitoylethanolamide vs NSAID in the treatment of TMJD Pain | Journal of Dental Research | 2010: 89(Special Issue B)
[67]: Ständer S, Raap U, Weisshaar E, Schmelz M, Mettang T, Handwerker H, Luger TA. | Pathogenesis of pruritus. | J Dtsch Dermatol Ges. | 2011 Jun;9(6):456-463. doi: 10.1111/j.1610-0387.2011.07585.x. Epub 2011 Jan 5.
[68]: Latif S, Fraga G, Gadzia J. | Increased mast cell density in capecitabine-induced hand-foot syndrome: a new pathologic finding. | J Drugs Dermatol. | 2010 Mar;9(3):268-70.
[69]: Papadoukakis S, Kyroudi-Voulgari A, Truss MC, Perea D, Mitropoulos D. | Quantitative study of mast cells in experimentally induced benign prostatic hyperplasia. | Urol Int. | 2010;84(1):100-4. Epub 2010 Feb 17.
[70]: Papadoukakis S, Kyroudi-Voulgari A, Truss MC, Perea D, Mitropoulos D. | Quantitative study of mast cells in experimentally induced benign prostatic hyperplasia. | Urol Int. | 2010;84(1):100-4. Epub 2010 Feb 17.
[71]: Mehik A, Leskinen MJ, Hellström P. | Mechanisms of pain in chronic pelvic pain syndrome: influence of prostatic inflammation. | World J Urol. | 2003 Jun;21(2):90-4. Epub 2003 Apr 17.
[72]: Butrick CW, Howard FM, Sand PK. | Diagnosis and treatment of interstitial cystitis/painful bladder syndrome: a review. |J Womens Health (Larchmt). | 2010 Jun;19(6):1185-93.
[73]: Richter B, Roslind A, Hesse U, Nordling J, Johansen JS, Horn T, Hansen AB. | YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis. | Histopathology. | 2010 Sep;57(3):371-83. doi: 10.1111/j.1365-2559.2010.03640.x.
[74]: Geurts N, Van Dyck J, Wyndaele JJ. | Bladder pain syndrome: do the different morphological and cystoscopic features correlate? | Scand J Urol Nephrol. | 2011 Feb;45(1):20-3. Epub 2010 Sep 17.
[75]: Richter B, Hesse U, Hansen AB, Horn T, Mortensen SO, Nordling J. | Bladder pain syndrome/interstitial cystitis in a Danish population: a study using the 2008 criteria of the European Society for the Study of Interstitial Cystitis. | BJU Int. |2010 Mar;105(5):660-7. Epub 2009 Sep 14.
[76]: Larsen MS, Mortensen S, Nordling J, Horn T. | Quantifying mast cells in bladder pain syndrome by immunohistochemical analysis. | BJU Int. | 2008 Jul;102(2):204-7; discussion 207. Epub 2008 Jul 1.
[77]: Rudick CN, Bryce PJ, Guichelaar LA, Berry RE, Klumpp DJ. | Mast cell-derived histamine mediates cystitis pain. | PLoS One. | 2008 May 7;3(5):e2096.
[78]: van de Nieuwenhof HP, Hebeda KM, Bulten J, Otte-Holler I, Massuger LF, de Hullu JA, van Kempen LC. | Specific intraepithelial localization of mast cells in differentiated vulvar intraepithelial neoplasia and its possible contribution to vulvar squamous cell carcinoma development. | Histopathology. | 2010 Sep;57(3):351-62. doi: 10.1111/j.1365-2559.2010.03635.x. Epub 2010 Aug 19.
[79]: Bornstein J, Goldschmid N, Sabo E. | Hyperinnervation and mast cell activation may be used as histopathologic diagnostic criteria for vulvar vestibulitis. | Gynecol Obstet Invest. | 2004;58(3):171-8. Epub 2004 Jul 9.
[80]: Halperin R, Zehavi S, Vaknin Z, Ben-Ami I, Pansky M, Schneider D. | The major histopathologic characteristics in the vulvar vestibulitis syndrome. | Gynecol Obstet Invest. | 2005;59(2):75-9. Epub 2004 Nov 11.
[81]: Chadha S, Gianotten WL, Drogendijk AC, Weijmar Schultz WC, Blindeman LA, van der Meijden WI. | Histopathologic features of vulvar vestibulitis. | Int J Gynecol Pathol. | 1998 Jan;17(1):7-11.
[82]: Murina F. et al. Palmitoylethanolamide and polidatina in the treatment of vestibulodynia, and the reduction of the C fibre activation. Presented at the world congress of pathology of the vulva, Parigi, september 2011 | |
[83]: Harlow BL, He W, Nguyen RH. | Allergic reactions and risk of vulvodynia. | Ann Epidemiol. | 2009 Nov;19(11):771-7.
[84]: Goetsch MF, Morgan TK, Korcheva VB, Li H, Peters D, Leclair CM. | Histologic and receptor analysis of primary and secondary vestibulodynia and controls: a prospective study. | Am J Obstet Gynecol. | 2010 Jun;202(6):614.e1-8. Epub 2010 Apr 28.
[85]: Calabrò RS, Gervasi G, Marino S, Mondo PN, Bramanti P. | Misdiagnosed chronic pelvic pain: pudendal neuralgia responding to a novel use of palmitoylethanolamide. | Pain Med. | 2010 May;11(5):781-4. Epub 2010 Mar 22.
[86]: Indraccolo U, Barbieri F. | Effect of palmitoylethanolamide-polydatin combination on chronic pelvic pain associated with endometriosis: preliminary observations. | Eur J Obstet Gynecol Reprod Biol. | 2010 May;150(1):76-9. Epub 2010 Feb 21.
[87]: Fulghesu A et al. Pain during menstruation in young adults treated with palmitoylethanolamide and polidatina. Presented at the 16th world congress for child and adolescent gynaecology, Montpellier, 2010 | |
[88]: De Filippis D, D’Amico A, Iuvone T. | Cannabinomimetic control of mast cell mediator release: new perspective in chronic inflammation. | J Neuroendocrinol. | 2008 May;20 Suppl 1:20-5.
[89]: Theoharides TC, Alysandratos KD, Angelidou A, Delivanis DA, Sismanopoulos N, Zhang B, Asadi S, Vasiadi M, Weng Z, Miniati A, Kalogeromitros D. | Mast cells and inflammation. | Biochim Biophys Acta. | 2010 Dec 23. [Epub ahead of print]
[90]: Schicho R, Storr M. | Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases. | Can J Gastroenterol. | 2011 Jul;25(7):377-83.
[91]: Peterson CG, Sangfelt P, Wagner M, Hansson T, Lettesjö H, Carlson M. | Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. | Scand J Clin Lab Invest. | 2007;67(8):810-20.
[92]: Rognum TO, Brandtzaeg P. | IgE-positive cells in human intestinal mucosa are mainly mast cells. | Int Arch Allergy Appl Immunol. | 1989;89(2-3):256-60.
[93]: O’Sullivan SE, Kendall DA. | Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. | Immunobiology. | 2010 Aug;215(8):611-6. Epub 2009 Oct 14.
[94]: Lakhan SE, Kirchgessner A. | Neuroinflammation in inflammatory bowel disease. | J Neuroinflammation. | 2010 Jul 8;7:37.
[95]: Kraneveld AD, Rijnierse A, Nijkamp FP, Garssen J. | Neuro-immune interactions in inflammatory bowel disease and irritable bowel syndrome: future therapeutic targets. | Eur J Pharmacol. | 2008 May 13;585(2-3):361-74. Epub 2008 Mar 18.
[96]: Foley S, Garsed K, Singh G, Duroudier NP, Swan C, Hall IP, Zaitoun A, Bennett A, Marsden C, Holmes G, Walls A, Spiller RC. | Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. | Gastroenterology. | 2011 May;140(5):1434-43.e1. Epub 2011 Mar 23.
[97]: Chang JY, Talley NJ. | An update on irritable bowel syndrome: from diagnosis to emerging therapies. | Curr Opin Gastroenterol. | 2010 Nov 18. [Epub ahead of print]
[98]: Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, Rivara S, Mor M, Russo R, Maccarrone M, Antonietti F, Duranti A, Tontini A, Cuzzocrea S, Tarzia G, Piomelli D. | Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. | Proc Natl Acad Sci U S A. | 2009 Dec 8;106(49):20966-71. Epub 2009 Nov 19.
[99]: Blirando K, Milliat F, Martelly I, Sabourin JC, Benderitter M, François A. | Mast cells are an essential component of human radiation proctitis and contribute to experimental colorectal damage in mice. | Am J Pathol. | 2011 Feb;178(2):640-51.
[100]: Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, Rivara S, Mor M, Russo R, Maccarrone M, Antonietti F, Duranti A, Tontini A, Cuzzocrea S, Tarzia G, Piomelli D. | Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. | Proc Natl Acad Sci U S A. | 2009 Dec 8;106(49):20966-71. Epub 2009 Nov 19.
[101]: Taylor TJ, Youssef NN, Shankar R, Kleiner DE, Henderson WA. | The association of mast cells and serotonin in children with chronic abdominal pain of unknown etiology. | BMC Res Notes. | 2010 Oct 21;3:265.
[102]: Chang JY, Talley NJ. | An update on irritable bowel syndrome: from diagnosis to emerging therapies. | Curr Opin Gastroenterol. | 2010 Nov 18. [Epub ahead of print]
[103]: De Filippis D, Luongo L, Cipriano M, Palazzo E, Cinelli MP, de Novellis V, Maione S, Iuvone T. | Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. | Mol Pain. | 2011 Jan 10;7:3.
[104]: Petrosino S, Iuvone T, Di Marzo V. | N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. |Biochimie. | 2010 Jun;92(6):724-7. Epub 2010 Jan 21.
[105]: Endocannabinoid Research Group, De Filippis D, D’Amico A, Cipriano M, Petrosino S, Orlando P, Di Marzo V, Iuvone T. |Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. | Pharmacol Res. | 2010 Apr;61(4):321-8. Epub 2009 Nov 17.
[106]: Hoareau L, Buyse M, Festy F, Ravanan P, Gonthier MP, Matias I, Petrosino S, Tallet F, d’Hellencourt CL, Cesari M, Di Marzo V, Roche R. | Anti-inflammatory effect of palmitoylethanolamide on human adipocytes. | Obesity (Silver Spring). |2009 Mar;17(3):431-8. Epub 2009 Jan 8.
[107]: De Filippis D, D’Amico A, Cinelli MP, Esposito G, Di Marzo V, Iuvone T. | Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageenin-granuloma model in rats. | J Cell Mol Med. | 2009 Jun;13(6):1086-95. Epub 2008 Apr 18.
[108]: Machelska H. | Dual peripheral actions of immune cells in neuropathic pain. | Arch Immunol Ther Exp (Warsz). | 2011 Feb;59(1):11-24. Epub 2011 Jan 14.
[109]: Ständer S, Raap U, Weisshaar E, Schmelz M, Mettang T, Handwerker H, Luger TA. | Pathogenesis of 750g pruritus. | J Dtsch Dermatol Ges. | 2011 Jun;9(6):456-463. doi: 10.1111/j.1610-0387.2011.07585.x. Epub 2011 Jan 5.
[110]: Järvikallio A, Naukkarinen A, Harvima IT, Aalto ML, Horsmanheimo M. | Quantitative analysis of tryptase- and chymase-containing mast cells in atopic dermatitis and nummular eczema. | Br J Dermatol. | 1997 Jun;136(6):871-7.
[111]: Eberlein B, Eicke C, Reinhardt HW, Ring J. | Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). | J Eur Acad Dermatol Venereol. | 2008 Jan;22(1):73-82.
[112]: Petrosino S, Cristino L, Karsak M, Gaffal E, Ueda N, Tüting T, Bisogno T, De Filippis D, D’Amico A, Saturnino C, Orlando P, Zimmer A, Iuvone T, Di Marzo V. | Protective role of palmitoylethanolamide in contact allergic dermatitis. | Allergy. | 2010 Jun 1;65(6):698-711. Epub 2009 Nov 11.
[113]: Kircik L. | A nonsteroidal lamellar matrix cream containing palmitoylethanolamide for the treatment of atopic dermatitis. | J Drugs Dermatol. | 2010 Apr;9(4):334-8.
[114]: Hatano Y, Man MQ, Uchida Y, Crumrine D, Mauro TM, Feingold KR, Elias PM, Holleran WM. | Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators.J Allergy Clin Immunol. | 2010 Jan;125(1):160-9.e1-5. Epub 2009 Oct 8.
[115]: Dahten A, Koch C, Ernst D, Schnöller C, Hartmann S, Worm M. | Systemic PPARgamma ligation inhibits allergic immune response in the skin. | J Invest Dermatol. | 2008 Sep;128(9):2211-8. Epub 2008 Apr 10.
[116]: Cerrato S, Brazis P, Valle MF, Miolo A, Petrosino S, Marzo VD, Puigdemont A. | Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. | Vet J. | 2011 May 19. [Epub ahead of print]
[117]: Harvima IT, Nilsson G, Naukkarinen A. | Role of mast cells and sensory nerves in skin inflammation. | G Ital Dermatol Venereol. | 2010 Apr;145(2):195-204.
[118]: Kneilling M, Röcken M. | Mast cells: novel clinical perspectives from recent insights. | Exp Dermatol. | 2009 May;18(5):488-96.
[119]: Harvima IT, Nilsson G, Suttle MM, Naukkarinen A. | Is there a role for mast cells in psoriasis? | Arch Dermatol Res. |2008 Oct;300(9):461-78. Epub 2008 Aug 22.
[120]: Broide DH, Finkelman F, Bochner BS, Rothenberg ME. | Advances in mechanisms of asthma, allergy, and immunology in 2010. | J Allergy Clin Immunol. | 2011 Mar;127(3):689-95.
[121]: Di Capite JL, Bates GJ, Parekh AB. | Mast cell CRAC channel as a novel therapeutic target in allergy. | Curr Opin Allergy Clin Immunol. | 2011 Feb;11(1):33-8.
[122]: Zhao J, Endoh I, Hsu K, Tedla N, Endoh Y, Geczy CL. | S100A8 modulates mast cell function and suppresses eosinophil migration in acute asthma. | Antioxid Redox Signal. | 2011 May 1;14(9):1589-600. Epub 2011 Feb 28.
[123]: Metz M, Gilles S, Geldmacher A, Behrendt H, Traidl-Hoffmann C, Maurer M. | Evidence for non-allergic mast cell activation in pollen-associated inflammation. | J Invest Dermatol. | 2011 Apr;131(4):987-90. Epub 2011 Jan 20.
[124]: Ozben B, Erdogan O. | The role of inflammation and allergy in acute coronary syndromes. | Inflamm Allergy Drug Targets. | 2008 Sep;7(3):136-44.
[125]: Kounis NG. | Kounis syndrome (allergic angina and allergic myocardial infarction): a natural paradigm? | Int J Cardiol. |2006 Jun 7;110(1):7-14. Epub 2005 Oct 24.
[126]: Biteker M. | Current understanding of Kounis syndrome. | Expert Rev Clin Immunol. | 2010 Sep;6(5):777-88.
[127]: Wilensky RL, Hamamdzic D. | The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation. | Curr Opin Cardiol. | 2007 Nov;22(6):545-51.
[128]: Pescosolido N, Librando A, Puzzono M, Nebbioso M. | Palmitoylethanolamide Effects on Intraocular Pressure After Nd:YAG Laser Iridotomy: An Experimental Clinical Study. | J Ocul Pharmacol Ther. | 2011 Aug 10. [Epub ahead of print]
[129]: Chen J, Matias I, Dinh T, Lu T, Venezia S, Nieves A, Woodward DF, Di Marzo V. | Finding of endocannabinoids in human eye tissues: implications for glaucoma. | Biochem Biophys Res Commun. | 2005 May 20;330(4):1062-7.
[130]: Caterina Gagliano et al | Ocular hypotensive effect of oral palmitoylethanolamide: a clinical trial. | Invest. Ophthalmol. Vis. Sci. June 24, 2011 iovs.10-7057 |
[131]: Yu HL, Deng XQ, Li YJ, Li YC, Quan ZS, Sun XY. | N-palmitoylethanolamide, an endocannabinoid, exhibits antidepressant effects in the forced swim test and the tail suspension test in mice. | Pharmacol Rep. | 2011 May-Jun;63(3):834-9.
[132]: Murillo-Rodríguez E, Palomero-Rivero M, Millán-Aldaco D, Arias-Carrión O, Drucker-Colín R. | Administration of URB597, Oleoylethanolamide or Palmitoylethanolamide Increases Waking and Dopamine in Rats. | PLoS One. | 2011;6(7):e20766. Epub 2011 Jul 14.
[133]: Romani R, Galeazzi R, Rosi G, Fiorini R, Pirisinu I, Ambrosini A, Zolese G. | Anandamide and its congeners inhibit human plasma butyrylcholinesterase. Possible new roles for these endocannabinoids? | Biochimie. | 2011 Sep;93(9):1584-91. Epub 2011 May 31.
[134]: Scuderi C, Esposito G, Blasio A, Valenza M, Arietti P, Steardo L Jr, Carnuccio R, De Filippis D, Petrosino S, Iuvone T, Di Marzo V, Steardo L. | Palmitoylethanolamide counteracts reactive astrogliosis induced by beta-amyloid peptide. | J Cell Mol Med. | 2011 Jan 21. doi: 10.1111/j.1582-4934.2011.01267.x. [Epub ahead of print]

[135]: Esposito E, Paterniti I, Mazzon E, Genovese T, Di Paola R, Galuppo M, Cuzzocrea S. | Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. | Brain Behav Immun. | 2011 Feb 25.